ORG 26576

Drug Profile

ORG 26576

Alternative Names: ORG26576

Latest Information Update: 17 Mar 2010

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Cortex Pharmaceuticals
  • Developer Merck & Co
  • Class Isoxazoles
  • Mechanism of Action AMPA receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Attention-deficit hyperactivity disorder; Major depressive disorder

Most Recent Events

  • 20 Jun 2008 Phase-I/II clinical trials in Attention-deficit hyperactivity disorder in USA (PO)
  • 20 Jun 2008 Phase-I/II clinical trials in Depression in USA (PO)
  • 19 Nov 2007 Organon has been acquired and merged into Schering-Plough
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top